Responses
Clinical/translational cancer immunotherapy
Original research
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
